A team of life science sector experts from Gowling WLG has advised Kelso Pharma in partnership with the healthcare specialist private equity investor, Apposite Capital on the acquisition of Stirling Anglian Pharmaceuticals Limited.

The Kelso Pharma team has extensive experience of building and running European specialty pharma businesses through M&A and licensing transactions. The acquisition of Stirling Anglian provides an initial UK platform and a springboard for future sales growth through further acquisitions, product in-licensing and geographic expansion within Europe.

The legal team that advised Kelso Pharma was made up of corporate partner Ian Piggin, principal associate Stephen Bowman and associate Alex Farrow and IP senior associate Christopher Freeth.

Ian said: "It has been a pleasure to assist on this key acquisition in the life sciences space which will help provide a new a higher level of competition to drive standards for end-users and customers."

Tom Stratford who is chief executive of Kelso Pharma said: "Our aim is to enhance value for the healthcare system by providing branded medicines that improve the lives of patients in a cost-effective and ethical way.

"Stirling Anglian's business is a perfect fit with our vision of enhancing value within healthcare with Apposite Capital's financial providing us with an ideal UK platform from which to grow. Gowling WLG's legal advice and support has been an invaluable element of this acquisition's delivery."

Gowling WLG's global life sciences team played an important part in the response to COVID-19, advising on three key projects relating to potential vaccines.